(Nevada, Las Vegas) The United States, DelveInsight’s, “Dry Age-Related Macular Degeneration – Pipeline Insight, 2023,” report provides comprehensive insights about 58+ companies and 64+ pipeline drugs in Dry Age-Related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Dry Age Macular Degeneration Pipeline Report
Over 58+ companies and 64+ pipeline drugs Dry Age Macular Degeneration pipeline therapies are in various stages of development, and their anticipated acceptance in the Dry Age Macular Degeneration market would significantly increase market revenue.
Leading Dry Age Macular Degeneration companies developing novel drug candidates to improve include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, and many others
Promising Dry Age Macular Degeneration pipeline therapies in various stages of development include ALK-001, Elamipretide, CPCB-RPE1, and many others
Dry Age Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. One of the top four causes of blindness in the elderly is AMD. It is also the leading cause of irreversible blindness in the developed countries. A total population of about 170 million individuals is affected with AMD globally, thus being the third leading cause of vision loss in the world. Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. No symptoms appear during the early stage of the disease
Discover more about the emerging Dry Age Macular Degeneration drugs @ Dry Age Macular Degeneration Treatment Drugs
Dry Age Macular Degeneration Pipeline Therapies and Key Companies
Molecular Partners : ALK-001, Elamipretide, CPCB-RPE1
Stealth BioTherapeutics: Elamipretide
Regenerative : CPCB-RPE1
And many others
Dry Age Macular Degeneration Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 64 + products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Dry Age Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the Dry Age Macular Degeneration Pipeline Report
Coverage: Global
Key Dry Age Macular Degeneration Companies: Concert Pharmaceutical, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others
Key Dry Age Macular Degeneration Pipeline Therapies: Deuruxolitinib, EQ101, MAX 40070, and others.
Find out more about the Dry Age Macular Degeneration treatment options in development @ Dry Age Macular Degeneration Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
